



DEPARTMENT OF HEALTH AND HUMAN SERVICES

MJ797n

Food and Drug Administration
Cincinnati District Office
Central Region
6751 Steger Drive
Cincinnati, OH 45237-30977
Telephone: (513) 679-2700
FAX: (513) 679-2772

WARNING LETTER

July 16, 1999

Cin WL-99-317

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

James M. Lieberman, M.D.
Medical Director
University Mednet - Mentor
9000 Mentor Ave.
Mentor, OH 44060

Inspection I.D.#: 1649130004

Dear Dr. Lieberman:

A representative from the State of Ohio radiation control program under contract to the Food and Drug Administration inspected your facility on June 24, 1999. This inspection revealed that your facility failed to comply with the Quality Standards for Mammography (Standards) as specified in Title 21, Code of Federal Regulations (CFR), Part 900.12, as follows:

Your records lack the required information that the following interpreting physician is qualified to interpret mammograms: [REDACTED] Your records did not demonstrate that [REDACTED] is licensed in Ohio to practice medicine.

The specific deficiency noted above appeared under the Level 1 heading on your MQSA Facility Inspection Report, which was issued at the close of the inspection. This deficiency may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility.

In addition, your response should address the **Level 2 Repeat** noncompliance that was listed on the inspection report provided to you at the close of the inspection. This Level 2 Repeat noncompliance is:

Your records show that the interpreting physician, [REDACTED] has not read or interpreted a minimum of 960 patient examinations in a 24 month period.

It is your responsibility to ensure adherence to each requirement of the Mammography Quality Standards Act of 1992 (MQSA) and FDA's regulations. You are responsible for investigating and determining the causes of the deficiencies that the inspection identifies and promptly initiate permanent corrective actions.

If you fail to promptly correct these deficiencies, FDA may, without further notice, initiate regulatory action. Under MQSA, FDA may:

impose civil money penalties on a facility of up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards.

suspend or revoke a facility's FDA certificate for failure to comply with the Standards.

seek an injunction in federal court to prohibit any mammography activity that constitutes a serious risk to human health.

Within 15 working days after receiving this letter, you should notify FDA in writing of:

the specific steps you have taken to correct all of the violations noted in this letter;

each step your facility is taking to prevent the recurrence of similar violations;

equipment settings (including technique factors), raw test data, and calculated final results, where appropriate; and

sample records that demonstrate proper record keeping procedures, if the noncompliances that were found relate to quality control or other records (Note: Patient names or identification should be deleted from any copies submitted).

If your facility is unable to complete the corrective action within 15 working days, you should state the reason for the delay and the time within which the corrections will be completed.

Please send the original copy of your response to:

Mr. R. Terry Bolen
MQSA Radiological Health Officer
Food and Drug Administration
6751 Steger Drive
Cincinnati, OH 45237-3097.

Also, send a copy to the State radiation control office:

Ms. Teri Eckert
Ohio Department of Health
Northeast District Office
Oliver R. Ocasek Government Office Building
161 S. High St. Suite 400
Akron, OH 44308-1616

If you have any questions regarding this letter or how to ensure you are meeting MQSA standards, please call R. Terry Bolen at (513)679-2700, extension 138.

Sincerely yours,

A handwritten signature in cursive script that reads "Henry L. Fielden".

Henry L. Fielden
District Director
Cincinnati District Office

c.
OH/TEckert